Evident LogoOlympus Logo

Ask the Experts

Hiroya Ishihara
Hiroya Ishihara

Hiroya Ishihara

Applications Scientist

Mr. Hiroya Ishihara is an Application Scientist at Olympus. He was studying the epigenetic factors involved in plant regeneration using omics and microscopy in Tokyo University of Science. Confocal and two-photon microscopy were his trusted partner at that time. Therefore, he joined Olympus to make life science more exciting with microscopes. Currently, he is working on a wide range of projects from basic research to product/sales strategy.

Ask the Experts

NoviSight™ Demonstration: 3D Image Analysis and Statistical Software for Organoids and Spheroids

NoviSight™ Demonstration: 3D Image Analysis and Statistical Software for Organoids and Spheroids

Experts
Hiroya Ishihara
Applications Scientist
Olympus Technologies Asia, Olympus Corporation
Three-dimensional cell culture models such as patient-derived organoids (PDO) and spheroids have increased in popularity because they can provide a 3D microenvironment that more closely reproduces in vivo conditions compared to 2D monolayer culture. Phenotypic and functional heterogeneity arise among cancer cells within the same tumor because of genetic change, environmental differences and reversible changes in cell properties. Therefore, evaluation of cell-specific responses is important for accurate prediction of drug efficacy and kinetics in vivo.

Three-Dimensional High-Throughput Image Analysis of Patient-Derived Organoids and Spheroids

Experts
Hiroya Ishihara
Applications Scientist
Olympus Technologies Asia, Olympus Corporation
Organoids and spheroids can more faithfully reproduce in vivo conditions, and imaging-based analysis can monitor cell-specific responses with high spatial resolution. Therefore, we have been developing imaging-based three-dimensional analysis and drug evaluation methods using patient-derived cancer organoids and spheroids.
InSight Blog Sign-up
You will be unable to submit the form unless you turn your javascript on.

By clicking subscribe you are agreeing to our privacy policy which can be found here.

Sorry, this page is not
available in your country.

Sorry, this page is not available in your country